Neurology & Neurosurgery

REI Week 2025 empowers the future in pediatric research and innovation

Children’s National Hospital hosted its fifteenth annual Research, Education and Innovation Week from March 31–April 4, 2025, bringing together clinicians, scientists, educators and innovators from across the institution to celebrate discovery and collaboration. This year’s theme, “Empowering the Future in Pediatric Research and Innovation with Equity, Technology and a Global Reach,” served as a call to action for advancing science that improves child health both locally and around the world.

Each day of the week-long event featured thought-provoking lectures — now available to watch — dynamic panel discussions, interactive workshops and vibrant poster sessions, all highlighting the diverse and interdisciplinary work taking place across Children’s National.

Centering the patient and the planet

REI Week began on Monday with a powerful keynote lecture from Lynn R. Goldman, MD, MS, MPH, Michael and Lori Milken dean of the Milken Institute School of Public Health at the George Washington University. In her talk, “Children: Uniquely vulnerable to climate-related threats,” Dr. Goldman underscored the urgent need to protect children from the environmental hazards of a changing climate and to integrate climate science into pediatric care and advocacy.

At mid-morning, Mary-Anne “Annie” Hartley, MD, PhD, MPH, director of the LiGHT Laboratory at École Polytechnique Fédérale de Lausanne, introduced the “MOOVE” platform — Massive Open Online Validation and Evaluation of clinical LLMs. Her talk demonstrated how artificial intelligence, when rigorously validated, has the potential to transform clinical decision-making and global health equity.

Monday’s final keynote, “Zinc and childhood diarrhea,” was presented by Christopher Duggan, MD, MPH, director of the Division of Nutrition at Harvard Medical School. Dr. Duggan highlighted the global health impact of zinc supplementation in reducing childhood mortality — a reminder that simple, evidence-based interventions can save millions of lives.

In that first day, the first poster session of the week showcased projects in adolescent medicine, global health, infectious diseases, oncology and more. The session reflected the full breadth of research taking place across Children’s National.

Ambroise Wonkam, MD, PhD, professor of genetic medicine at Johns Hopkins University, then delivered Tuesday’s Global Health Keynote Lecture, “Harnessing our common African genomes to improve health and equity globally.” His work affirmed that inclusive genomics is key to building a healthier world.

Later, the Global Health Initiative event and GCAF Faculty Seminar encouraged attendees to pursue collaborative opportunities at home and abroad, reflecting the growing global footprint of Children’s National research programs.

Transforming education and care delivery

On Wednesday, Larrie Greenberg, MD, professor emeritus of pediatrics, kicked off the day with a Grand Rounds keynote on educational transformation: “Shouldn’t teachers be more collaborative with their learners?” He followed with a CAPE workshop exploring the effectiveness of case-based learning.

The Nursing Sponsored Keynote Lecture by Vincent Guilamo-Ramos, PhD, MPH, LCSW, ANP-BC, PMHNP-BC, FAAN, explored “Redesigning the U.S. broken health system.” He offered an urgent and inspiring call to reimagine pediatric care by addressing social determinants of health.

In the Jill Joseph Grand Rounds Lecture, Deena J. Chisolm, PhD, director of the Center for Child Health Equity at Nationwide Children’s Hospital, challenged attendees to move beyond dialogue into action in her talk, “Health equity: A scream to a whisper?,” reminding researchers and clinicians that advocacy and equity must be foundational to care.

The day continued with a poster session spotlighting medical education, neonatology, urology and neuroscience, among other fields.

Posters and pathways to progress

Throughout the week, poster sessions highlighted cutting-edge work across dozens of pediatric disciplines. These sessions gave attendees the opportunity to engage directly with investigators and reflect on the shared mission of discovery across multiple disciplines, including:

Honoring excellence across Children’s National

The REI Week 2025 Awards Ceremony celebrated outstanding contributions in research, mentorship, education and innovation. The winners in each category were:

POSTER SESSION AWARDS

Basic & Translational Research

Faculty:  Benjamin Liu, PhD

“Genetic Conservation and Diversity of SARS-CoV-2 Envelope Gene Across Variants of Concern”

Faculty:  Steve Hui, PhD
“Brain Metabolites in Neonates of Mothers with COVID-19 Infection During Pregnancy”

Faculty: Raj Shekhar, PhD
“StrepApp: Deep Learning-Based Identification of Group A Streptococcal (GAS) Pharyngitis”

Post docs/Fellows/Residents: Dae-young Kim, PhD
“mhGPT: A Lightweight Domain-Specific Language Model for Mental Health Analysis”

Post docs/Fellows/Residents: Leandros Boukas, MD, PhD
“De Novo Variant Identification From Duo Long-Read Sequencing: Improving Equitable Variant Interpretation for Diverse Family Structures”

Staff: Naseem Maghzian
“Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC)”

Graduate Students: Abigail Haffey
“Synergistic Integration of TCR and CAR T Cell Platforms for Enhanced Adoptive Immunotherapy in Brain Tumors”

High School/Undergraduate Students: Medha Pappula
“An ADHD Diagnostic Interface Based on EEG Spectrograms and Deep Learning Techniques”

Clinical Research

Faculty: Folasade Ogunlesi, MD
“Poor Air Quality in Sub-Saharan Africa is Associated with Increase Health Care Utilization for Pain in Sickle Cell   Disease Patients”

Faculty: Ayman Saleh, MD
“Growth Parameters and Treatment Approaches in Pediatric ADHD: Examining Differences Across Race”

Post docs/Fellows/Residents: Nicholas Dimenstein, MD, MPH
“Pre-Exposure Prophylaxis (PrEP) Eligibility in the Pediatric Emergency Department”

Staff: Tayla Smith, MPH
“The Public Health Impact of State-Level Abortion and    Firearm Laws on Health Outcomes”

Graduate Students: Natalie Ewing
“Patterns of Bacteriuria and Antimicrobial Resistance in Patients Presenting for Primary Cloacal Repair: Is Assisted Bladder Emptying Associated with Bacteriuria?”

Graduate Students: Manuela Iglesias, MS
“Exploring the Relationship Between Child Opportunity Index and Bayley-III Scores in Young Children”

High School/Undergraduate Students: Nicholas Lohman
“Preliminary Findings: The Efficacy, Feasibility and Acceptability of Group Videoconference Cognitive Behavioral Therapy with Exposure and Response Prevention for Treating Obsessive-Compulsive Disorder Among Children and Young People”

Community-Based Research

Faculty: Sharon Shih, PhD
“Assessing Pediatric Behavioral Health Access in DC using Secret Shopper Methodology”

Post docs/Fellows/Residents: Georgios Sanidas, MD
“Arrested Neuronal Maturation and Development in the Cerebellum of Preterm Infants”

Staff: Sanam Parwani

“Intersectionality of Gender and Sexuality Diversity in Autistic and Non-Autistic Individuals”

Graduate Student: Margaret Dearey
“Assessing the Burden of Period Poverty for Youth and Adolescents in Washington, DC: A Pilot Study”

Quality and Performance Improvement

Faculty: Nichole L. McCollum, MD
“A Quality Improvement Study to Increase   Nurse Initiated Care from Triage and Improve Timeliness to Care”

Post docs/Fellows/Residents:  Hannah Rodriguez, MD
“Reducing Unnecessary Antibiotic Use in a Level IV NICU”

Staff: Amber K. Shojaie, OTD, OTR/L
“Implementing Dynamic Axilla Splints in a Large Burn Patient”

MENTORSHIP AWARDS

Basic Science Research

Conrad Russell Y. Cruz, MD, PhD

Clinical Research

Rana Hamdy, MD, MPH, MSCE

Bench to Bedside Research

Ioannis Koutroulis, MD, PhD, MBA

ELDA ARCE TEACHING SCHOLAR AWARD

Priti D. Bhansali, MD, MEd

Heather Ann Walsh, PhD, RN

SUZANNE FEETHAM NURSING RESEARCH SUPPORT AWARD

Eileen P. Engh, PhD RN 
“Rare Disease Organization Lifecycle” Role in Helping Parents with Everyday Life Information Seeking and Connection (RDO-HELIX)

EXPLORATIONS IN GLOBAL HEALTH PILOT AWARDS

Launchpad Awards

Mi Ran Shin, MD, MPH
“Establishing Interdisciplinary Rehabilitation for Birth and Burn Injuries in Ethiopia”

Susan Harvey, MSN, CPNP-AC
“Implementation of Sickle Cell Pilot Program in Ndhiwa Sub County, Kenya”

Meleah Boyle, PhD, MPH
“Understanding and Addressing Environmental Sustainability to Protect the Health of the Children’s National and Global Communities”

Eiman Abdulrahman, MD
“Research Capacity Building to Improve Pediatric Emergency and Critical Care in Ethiopia”

Pilot Awards

Alexander Andrews, MD
“EEG as a Diagnostic and Prognostic Marker in Severe Pediatric Malaria, Blantyre Malawi”

Daniel Donoho, MD & Timothy Singer, MD
“Feasibility Study of a Novel Artificial Intelligence-Based Educational Platform to Improve Neurosurgical Operative Skills in Tanzania”

Hasan Syed, MD
“Bridging the Gap an Educational Needs Assessment for Pediatric Neurosurgery Training in Pakistan”

Sofia Perazzo, MD & Lamia Soghier, MD, MEd, MBA
“QI Mentorship to Improve Pediatric Screening and Follow-up in Rural Argentina”

Benjamin Liu, PhD
“AI-Empowered Real-Time Sequencing Assay for Rapid Detection of Schistosomiasis in Senegal”

Rae Mittal, MD
“Assessment and Enhancement of Proficiency in Emergency Child Neurology Topics for Post-Graduate Emergency Medicine Trainees in India”

Innovation Day ignites bold thinking

Thursday, REI Week shifted to the Children’s National Research & Innovation Campus for Innovation Day, a celebration of how bold ideas and collaborative culture can accelerate progress in pediatric medicine.

Brandy Salmon, PhD, associate vice president of Innovation and Partnerships at Virginia Tech, opened the day with “The Alchemy of Innovation,” focusing on how institutions can build a culture that fuels transformative partnerships.

A multidisciplinary panel discussion moderated by Nathan Kuppermann, MD, MPH, and Catherine Bollard, MBChB, MD, featured Nehal Mehta, MD, Julia Finkel, MD, Kevin Cleary, PhD, Ioannis Koutroulis, MD, PhD, MBA, Francesca Joseph, MD and Patrick Hanley, PhD, who shared how innovation can be advanced and promoted, especially as a core institutional priority.

A shared vision for the future

REI Week 2025 reaffirmed the values that define Children’s National: a commitment to excellence, collaboration and equity in pediatric research and care. As discoveries continue to emerge from our hospital and our research campuses, the connections built and ideas sparked during this week will help shape the future of pediatric health — locally and globally.

By elevating voices from the bedside to the bench, with the support of the executive sponsors Nathan Kuppermann, MD, MBChB, Catherine Bollard, MBChB, MD, Kerstin Hildebrandt, MSHS, Linda Talley, MS, RN, NE-BC and David Wessel, MD, REI Week demonstrated that we must embrace the community in all aspects of our work. Because we know that there are answers we can only get from the patients that we serve—and we need to be their voice.

Research, Education & Innovation Week will be back next year on April 13-17, 2026.

  • Posters at the REI Week 2025 Monday, March 31 poster session.

    Posters at the REI Week 2025 Monday, March 31 poster session.
  • Panelists discuss innovation during REI Week 2025.

    Panelists discuss innovation during REI Week 2025.
  • Global Health Initiative community engagement event during REI Week 2025.

    Global Health Initiative community engagement event during REI Week 2025.
  • Chris Rees presents his REI Week 2025 lecture.

    Chris Rees presents his REI Week 2025 lecture.
  • Nathan Kuppermann listens to a presenter during the REI Week 2025 Tuesday, April 1, poster session.

    Nathan Kuppermann listens to a presenter during the REI Week 2025 Tuesday, April 1, poster session.
  • Michelle Riley-Brown, Nathan Kuppermann, Catherine Bollard and Naomi Luban on stage during the REI Week 2025 awards ceremony.

    Michelle Riley-Brown, Nathan Kuppermann, Catherine Bollard and Naomi Luban on stage during the REI Week 2025 awards ceremony.
  • Brandy Salmon presents on innovation programs at Virginia Tech during the REI Week 2025 Innovation Day.

    Brandy Salmon presents on innovation programs at Virginia Tech during the REI Week 2025 Innovation Day.
  • Catherine Bollard listens to a presenter during the REI Week 2025 Monday, March 21 poster session.

    Catherine Bollard listens to a presenter during the REI Week 2025 Monday, March 21 poster session.
  • Ambroise Wonkman poses for a picture with Children’s National staff.

    Ambroise Wonkman poses for a picture with Children’s National staff.
  • Tanzeem Choudhury presenting during REI Week 2025.

    Tanzeem Choudhury presenting during REI Week 2025.

Pioneering NF innovation and treatment: Q&A with Benjamin Siegel, MD

Benjamin Siegel, MDFor more than four decades, Children’s National Hospital has been at the forefront of neurofibromatosis (NF) care, research and treatment. In 2007, Dan and Jennifer Gilbert furthered this mission by establishing the Gilbert Family Neurofibromatosis Institute in honor of their son Nick. The Gilberts have dedicated themselves to eradicating NF and improving the future for those affected. Their partnership with Children’s National has transformed the Institute into a global hub for NF care and innovation.

“Since 1982, we’ve combined compassionate care with cutting-edge innovation to provide the best outcomes for our patients while advancing NF treatment,” says Roger J. Packer, MD, director of the institute.

Dr. Packer leads a team of NF experts, including Benjamin Siegel, MD, clinical co-director of the institute, whose expertise in pediatric neurology and neuro-oncology is critical to the program’s success. In this Q&A, Dr. Siegel shares what sets Children’s National apart, how it benefits patients and the latest NF research advancements.

What makes the Gilbert Family Neurofibromatosis Institute at Children’s National unique from other programs in the country?

The Gilbert Family Neurofibromatosis Institute is the longest-running NF program in the United States, with over 40 years of leadership in advancing the field. We helped establish the initial diagnostic criteria in the 1980s and have been pivotal in chairing the Neurofibromatosis Clinical Trials Consortium. Our involvement in groundbreaking clinical trials led to FDA approval of the first targeted therapies for NF1-associated plexiform neurofibromas. Building upon this strong legacy, we continue to advance the future of care for those affected by NF.

Our multidisciplinary team, led by Sinan Turnacioglu, MD, and myself under Dr. Packer’s direction, integrates diverse expertise. My background in neurology and neuro-oncology, combined with Dr. Turnacioglu’s expertise in neurodevelopmental disabilities, allows us to provide comprehensive, high-quality care. With access to specialized clinical resources, we ensure each patient receives the most informed and well-rounded treatment.

How does the work in this program benefit patients?

Our program’s success lies in its comprehensive, interdisciplinary approach to patient care. NF and schwannomatosis can impact every organ system in the body, making close collaboration among specialists essential to address each patient’s unique needs. Our goal is to act as a “medical home” for individuals with NF, ensuring seamless, coordinated care across neurology, oncology, genetics, orthopedics, neurosurgery, plastic surgery, otolaryngology, endocrinology, cardiology and psychiatry.

Recent expansions include neuropsychology, led by Karin Walsh, PsyD, providing comprehensive clinical neuropsychological testing, and physical medicine and rehabilitation, where Mi Ran Shin, MD, MPH, helps manage musculoskeletal issues and chronic pain. This integrated approach allows us to address the complex concerns of NF patients effectively, improving both their physical function and quality of life.

How is Children’s National leading the way in NF research?

Children’s National is at the forefront of NF research, with groundbreaking translational studies spearheaded by its cutting-edge hospital laboratories. Our team is pioneering the use of organoid models to better understand malignant transformations in NF1-associated low-grade gliomas. With a focus on developing targeted therapies for currently untreatable high-grade gliomas, Children’s National has been selected as a key member of the newly funded Gilbert Family NF1-Assosiated Glioma Consortium, an initiative dedicated to advancing treatment options for NF1-associated gliomas.

As a founding member of the Neurofibromatosis Clinical Trials Consortium (NFCTC), we led pivotal clinical trials on targeted therapies for NF1 and schwannomatosis (NF2) tumors. In 2025, the consortium will launch three new trials focused on NF1-associated plexiform neurofibromas. In development are trials evaluating bone health in NF1, attention deficit disorder in NF1, preventative therapy for NF2-associated schwannomas and new treatments for high-grade gliomas and malignant peripheral nerve sheath tumors (MPNST).

Beyond the NFCTC, Children’s National is a member of the Pediatric Brain Tumor Consortium, contributing to selumetinib research for NF1 gliomas. Additionally, through the leadership of internationally known solid tumor oncologist AeRang Kim, MD, PhD, we’re involved with the Sarcoma Alliance for Research through Collaboration, with a focus on developing treatments for MPNST.

Dr. Walsh’s neuropsychology program has advanced understanding of NF1-related cognitive challenges through studies on MEK inhibitors’ effects on neurocognition and links between sleep disorders and ADHD. It also recently completed a pilot study on the Unstuck and On Target program to improve executive function in NF1.

What else is important for peers to know?

A diagnosis of NF or schwannomatosis can be overwhelming and frightening for families due to the wide range of symptoms and manifestations. This uncertainty can often lead to significant anxiety, as patients and their families may struggle to understand what to expect in terms of medical care, progression and treatment options.

At the Gilbert Family Neurofibromatosis Institute, we aim to ease this uncertainty by providing a comprehensive care approach. We offer not only cutting-edge clinical treatments but also support and guidance through the complexities of the disorder. Our team is committed to addressing concerns, providing updated information about the latest research and connecting families to ongoing clinical trials and support resources. By offering a personalized, multi-disciplinary approach, we help our patients navigate their diagnosis with greater confidence and hope for the future.

Looking ahead, Children’s National is set to advance NF research and care with a five-year grant from the Gilbert Family Foundation. The hospital will collaborate with global institutions to address NF-1 associated transformed gliomas and launch the first clinical study using molecular targeted therapy and immunotherapy to treat this aggressive tumor, marking a key milestone in its commitment to innovative treatments and improved outcomes for children with NF.

New study finds prenatal opioid exposure linked to smaller newborn brain volumes

brain scans of newbornA new study out of the Center for Prenatal, Neonatal & Maternal Health Research, directed by Catherine Limperopoulos, PhD, led by Yao Wu, PhD and Stephanie Merhar, MD, MS, out of Cincinnati Children’s Hospital Medical Center, sought answers to the question: “Do brain volumes differ in opioid-exposed vs. unexposed newborns?” In one of the largest studies of this kind, researchers found that prenatal exposure to opioids is associated with smaller brain volumes in newborns. These findings from the landmark Outcomes of Babies with Opioid Exposure (OBOE) study build on, reinforce smaller studies, and achieve a better understanding of the impacts of prenatal opioid exposure (POE).

Dive Deeper

The Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT-NOW)’s OBOE study is a multi-site observational study of newborns with prenatal opioid exposure and a control group of unexposed newborns from four different sites in the United States – Case Western Reserve University, Cincinnati Children’s Hospital Medical Center, University of Alabama at Birmingham, and Children’s Hospital of Philadelphia.

In a study involving 173 newborns who were exposed to opioids during pregnancy and 96 newborns not exposed to opioids prenatally showed smaller brain sizes in several key areas. Specifically, these exposed babies had smaller total brain volumes, as shown through MRI, as well as reduced volumes in important parts of the brain, including the cortex (outer layer of the brain), deep gray matter (areas that control movement and emotions), white matter (which helps transmit signals in the brain), cerebellum (responsible for coordination and movement), brainstem (controls basic functions like breathing), and the amygdala (involved in emotions and memory).

Further details showed that newborns exposed to medication for opioid use disorder (MOUD) during pregnancy with methadone, had smaller white matter volumes, while those exposed to MOUD with buprenorphine had smaller volumes specifically in the right amygdala. Additionally, newborns who were exposed to opioids plus additional substances such as THC and gabapentin had smaller volumes in even more brain areas compared to those who were only exposed to opioids.

What’s Next

The OBOE study sets the groundwork for further research into the long-term impact of opioid exposure during pregnancy. Additional work is necessary to expand on these findings and how they relate to functions in childhood – including exploring the way these reduced brain volumes may impact cognitive, behavioral, and motor impairments. The study raises important questions about how current guidelines for MOUD during pregnancy – specifically with methadone and buprenorphine – might evolve considering these findings. This study highlights the need for further research to assess the long-term effects of MOUD regimens on both maternal and infant outcomes.

This significant study underscores the importance of multi-disciplinary collaboration in opioid exposure research, effective regulation, and policy interventions – involving healthcare providers, researchers, policymakers, and affected families – to best mitigate the consequences and improve the health outcomes of children affected by prenatal opioid exposure.

You can read the full study, Antenatal Opioid Exposure and Global and Regional Brain Volumes in Newborns, and its companion editorial, Following the Developing Brain Affected by Opioid Exposure, in the Journal of the American Medical Association.

Additional authors from Children’s National include Kushal Kapse, BS, MS, and Josepheen De Asis-Cruz, MD, PhD. Other authors include Carla M. Bann, PhD, Jamie E. Newman, PhD4, Nicole Mack, MS, Sara B. De Mauro, MD, MSCE, Namasivayam Ambalavanan, MD, Jonathan M. Davis, MD, Scott A. Lorch, MD, MSCE5, Deanne Wilson-Costello, MD, Brenda B. Poindexter, MD and Myriam Peralta-Carcelen, MD.

Children’s National Hospital to host 35th Annual Pediatric Neurology Update

illustration of the brain on black backgroundThe Divisions of Neurology and Neurosurgery at Children’s National Hospital are proud to host the 35th Annual Pediatric Neurology Update course.

Chair Elizabeth Wells, MD; Co-Chairs, Marc DiSabella, DO, John Schreiber, MD, William D. Gaillard, MD, Robert Keating, MD

The course attracts a national audience and brings together neuroscience clinicians and pediatricians in the Washington, D.C. and Mid-Atlantic region.

Guest speakers include Annapurna Poduri, MD, MPH, Deputy Director for NINDS, Emily Freilich, MD, from the FDA and Conor Mallucci, MBBS, Chief of Neurosurgery at Alder Hays, England.

This year’s course highlights 3 major areas:

  • Updates in Epilepsy
  • Innovations in Vascular Neurosurgery and Neurointerventional Radiology
  • Addressing Mental and Behavioral Health in Neurological Conditions

We invite you to join us for presentations from experts in the field during this full-day, CME accredited event on April 10, 2025. This is a hybrid event that will be held virtually or in-person at the Children’s National Research & Innovation Campus.

For more information and to register, visit ChildrensNational.org/NeurologyUpdate.

U.S. News & World Report voting

U.S. News & World Report badgeChildren’s National is ranked one of the top 10 pediatric hospitals in the nation by U.S. News & World Report. Our faculty and staff are proud of the impact made on the lives of children and families in our community. Your participation in the U.S. News & World Report annual reputational survey validates the quality of care we provide and reflects the mutual respect and trust we share as healthcare professionals.

How to determine your voting eligibility

Voting for the U.S. News & World Report Best Children’s Hospitals rankings can be done only through Doximity.

To participate, physicians must:

  • Be board-certified and meet the eligibility criteria for the voting categories.
  • For child and adolescent psychologists, your account must be up to date with your specialty and subspecialty correctly marked.
  • Be a credential-verified member of Doximity (you must have an active and claimed Doximity profile).
  • Have all certifications and board documents currently up-to-date in your Doximity profile.

View the full eligibility criteria

How to claim your Doximity profile to vote

  • You have to claim your profile on Doximity.com to participate in the online survey. If you have not yet claimed your Doximity profile, go to Doximity.com, and click “Find My Profile.”
  • Once your profile has been claimed, you must confirm your email address and board certifications.
  • Verified Doximity members will receive an email inviting them to participate in the U.S. News survey.
  • For more information on how to claim your profile, visit Doximity.com

How to update and verify existing Doximity account information

Your Doximity profile must have up-to-date licenses, certifications and board documents.

  • Once you are logged in, your profile will automatically be in “Edit Mode.” You are able to add new items or edit existing information.
  • Update your Doximity profile and ensure your information is current.

Once registered, users wishing to participate in the online survey should:

  • Watch for an email from Doximity about the annual member survey.
  • Even if you don’t see the email, if you are a registered Doximity user, you can still vote by logging in to Doximity.com with your username and password during the voting period.
  • Once logged in, look for a U.S. News graphic or button on the homepage and click on it.
  • The survey asks users to name the hospitals that provide the best care in your respective specialty, without consideration to location or cost. Pediatric specialists will list 10 hospitals. The order in which you list the hospitals does not matter.

Please note: Children’s National Hospital is listed as “Children’s National Hospital Washington, DC” on the survey.

Visit Doximity’s FAQs if you have issues or questions about registration or claiming your profile.

How to cast your vote

In February 2025 when voting opens, all survey-eligible physicians will receive a notification on the Doximity app for Android or iOS. If you do not use the Doximity app, you will receive an email when voting opens.

  1. Log in to your Doximity account at doximity.com or via the mobile app.
  2. Click the Notifications icon or tap the “Submit your Nominations” button on the homepage. You can also search for “U.S. News Best Hospitals”
  3. Select 10 hospitals in your respective specialty that you believe provide the best care in the United States.
  4. Submit your vote

Having technical issues?

If you have difficulty registering with Doximity or completing the survey, please visit Doximity support for assistance.

Vote

The 2025 U.S. News & World Report Best Children’s Hospitals reputation voting will open in mid-February. Look for your Doximity notification to vote.

Study finds new genetic cause of neurodevelopmental disorders

Histological section of a brain.

Nissel staining of pre-clinical model brain.

A cross-disciplinary team of researchers and physicians from Children’s National Hospital and Washington University School of Medicine in St. Louis, in collaboration with physicians from around the world, identified a new genetic cause of neurodevelopmental disorders (NDDs). In a new study published in the American Journal of Human Genetics, researchers found 14 unrelated patients with 15 different sequence variants in HECTD1 – 10 missense, 3 frameshift, 1 nonsense and 1 splicing variant – with NDDs, including autism, attention-deficit/hyperactivity disorder (ADHD) and epilepsy.

Moving the field forward

Many patients suspected of having a genetic disorder remain undiagnosed. In about 10% of these cases, the genetic change is in a gene unknown to cause the disorder.

“Describing a new genetic cause of neurodevelopmental disorders will allow for the characterization of the gene’s role in brain development, the genetic syndrome and the mechanisms of disease,” says Irene Zohn, PhD, principal investigator in the Center for Genetic Medicine Research at Children’s National and co-lead of the study. “This information will lead to developing treatments to improve the lives of patients.”

The patient benefit

“Our study represents the first report of HECTD1 in NDDs,” says Dr. Zohn. “Now that this gene is linked to the disorder, clinicians with patients with sequence variation in this gene can enroll in studies to understand this new HECTD1 syndrome.”

Proper genetic diagnosis is important so that comorbidities and the natural history of the disorder can be described, which will lead to improvements in patient care.

What we hope to discover

Now that a new genetic syndrome has been defined, researchers hope to establish how prevalent the syndrome is and describe its features. Using pre-clinical models, they’ll continue to study the developmental basis of the disorder and the molecular mechanisms to develop therapies.

Children’s National leads the way

The HECTD1 gene was discovered in Dr. Zohn’s laboratory, and her research team connected with Christina Gurnett, MD, PhD, co-lead of the study from Washington University School of Medicine, to link this gene to human disease.

Additional authors from Children’s National include – Elias Oxman, Keito Ishibashi, Sonia Sebaoui, Kathryn Luedtke, Bryce Winrow, Seth Berger, MD, PhD, Christina L. Grant, MD, PhD, and Joshua Corbin, PhD.

You can read the full study Sequence Variants in HECTD1 Result in a Variable Neurodevelopmental Disorder in the American Journal of Human Genetics.

Review: New insights into brain development and behavior

The cover of Trends in Neurosciences

A recent review by researchers at Children’s National, published in Trends in Neurosciences, offers a new and in-depth understanding of how the amygdala is formed during fetal developmental.

The medial amygdala (MeA) is a central structure of the brain for regulation of social and emotional behaviors. Amygdala dysfunction is associated with a host of developmental conditions including autism spectrum disorders (ASD), post-traumatic stress disorder (PTSD) and the consequences of early life stress. To date, there has been a lack of comprehensive understanding of how the amygdala forms developmentally.

A recent review by researchers at Children’s National Hospital, published in Trends in Neurosciences, offers a new and in-depth understanding of how this complex structure is formed during fetal developmental and the role it plays in social behavior.

“This extensive review conveys the latest findings on how the amygdala is formed from development across preclinical models and humans,” says Joshua Corbin, PhD, interim director of the Center for Neuroscience Research at Children’s National and lead author of the review. “Past and present work in our lab has contributed critical knowledge of how this important structure forms from development and implications for human conditions.”

Moving the field forward

Malformation of the amygdala is a hallmark feature of disorders of social cognition such as ASD. Additionally, amygdala development is highly susceptible to early life stress and influences altered fear and anxiety responses in individuals who have been faced with early life stress.

“Despite our growing understanding of MeA development and its role in behavior, many critical questions remain. However, with cutting-edge tools like transcriptomic profiling, subcircuit-level circuit mapping, CRISPR mutagenesis and targeted gene delivery, we’re on the brink of uncovering different neurons in the amygdala form and shape social behaviors,” says Dr. Corbin.

Children’s National leads the way

Dr. Corbin’s team is among only a handful of groups in the world focused on understanding amygdala development. Investigators within the Center for Neuroscience Research at Children’s National have a shared goal of understanding the biological underpinnings of neurodevelopmental disorders.

You can read the full review published in Trends in Neurosciences. 

William D. Gaillard, MD, receives 2024 Clinical Science Research Award from AES

William D. Gaillard, MD

For his groundbreaking research in pediatric epilepsy care, William D. Gaillard, MD, has been named the recipient of the 2024 Clinical Science Research Award by the American Epilepsy Society (AES).

For his groundbreaking research in pediatric epilepsy care, William D. Gaillard, MD, has been named the recipient of the 2024 Clinical Science Research Award by the American Epilepsy Society (AES).

Dr. Gaillard serves as chief of the Divisions of Child Neurology and of Epilepsy and Neurophysiology, director of the Comprehensive Pediatric Epilepsy Program and associate director of the Center for Neuroscience Research at Children’s National Hospital. He also is Professor of Pediatrics and Neurology at the George Washington University School of Medicine, adjunct Professor of Neurology at Georgetown University and adjunct professor of Hearing and Speech Sciences at the University of Maryland, College Park. He holds the endowed Chair for Epilepsy and Neurophysiology.

About the award

This esteemed award, presented annually at AES, recognizes leading researchers whose work significantly contributes to the understanding and treatment of epilepsy. Dr. Gaillard’s groundbreaking research, which combines advanced imaging techniques with a focus on epilepsy and cognitive systems, has paved the way for important advances in the field of pediatric epilepsy care.

“It is a great honor to be recognized by my peers for the research I have conducted to improve the lives of children with epilepsy,” said Dr. Gaillard.

Dr. Gaillard’s work continues to have a profound impact on the field of pediatric neurology and epilepsy research. His commitment to advancing both scientific understanding and clinical outcomes for children with epilepsy has earned him the highest accolades from the AES. This recognition not only honors his past achievements but also highlights his ongoing contributions to the field, ensuring a brighter future for pediatric epilepsy care.

Pioneering evidence-based treatments for substance addictions

Sivabalaji Kaliamurthy, MD

“We really want to focus on intervening in an evidence-based manner in the primary care setting because that is where most of our patients are going to first access care outside of the emergency room,” says Dr. Kaliamurthy.

Increasing evidence-based treatment is a key component of the Addictions Program at Children’s National Hospital, created in 2022 and led by Sivabalaji Kaliamurthy, MD. In addition to evidence-based treatment and prevention efforts, the team also prioritizes engagement and education. The team collaborates with area pediatricians, who are often the first providers to identify substance use. Pediatric residents rotate with the program during their adolescent medicine blocks and child and adolescent psychiatry fellows have dedicated time with the Addictions Program to increase their knowledge and comfort in managing substance use and often co-occurring psychiatric disorders. “We really want to focus on intervening in an evidence-based manner in the primary care setting because that is where most of our patients are going to first access care outside of the emergency room,” says Dr. Kaliamurthy.

The challenge

The most common substances kids use or experiment with are alcohol, nicotine and cannabis. The team at Children’s National is focusing on the significant increase in potency of substances over the last decade. For example, cannabis potency is based on the amount of tetrahydrocannabinol (THC), and over the last 10 years, average potency in the plant product has gone from 2-5% THC to 20-25% THC. There are also higher potency products that can be vaped which contain upwards of 80% THC, which kids prefer due to ease in concealability. “It’s not the same drugs anymore that the parents’ generation might have used or experimented with when they were high schoolers, even though it’s still nicotine and cannabis, the potency has significantly changed,” says Dr. Kaliamurthy.

In addition to prevention tactics, the team at Children’s National is prioritizing the development of evidence-based treatment for patients in the Addictions Program. “Children need more tailored intervention that simply doesn’t have the same robust evidence basis that we have for adults. Right now, we are prioritizing implementing treatments that have been successful in limited research settings and studying how it translates into real world clinical settings for kids,” explains Dr. Kaliamurthy.

The challenge of treating cannabis use disorder and cannabis use disorder with co-occurring mental health conditions is that there are no effective FDA-approved medications for cannabis use disorder. Alcohol, opioids and nicotine all have many FDA-approved medication options for adults that can be used as part of a child’s treatment, off label. Dr. Kaliamurthy notes, “that is one of the directions that we will also be taking in the future — how we can effectively treat cannabis use and cannabis use co-occurring with very severe mental health conditions.”

What’s next?

Addressing community misinformation and the stigma surrounding substance use treatment has led to the development of several priority projects, including:

  • Increasing education and access to information for staff at Children’s National. Ensuring that if any clinician at Children’s National meets a child that is struggling, they know where to go for regional resources and what to do for next steps to get support and help for the patient. Dr. Kaliamurthy led a project to develop resources on an intranet site available to all staff.
  • Increasing access to care. Kaliamurthy is piloting a team of peer recovery support specialists. “We know that peers are people with lived experience who are in recovery, and they’ve been very effective in the adult world in really helping patients engage and connect with care.” This is a novel program launching with our youth in the emergency room.
  • Focusing on cannabis. With the increase in the number of kids coming to the hospital for cannabis-related reasons and the lack of effective treatments, we are going to be focusing on effectively treating cannabis use and cannabis use with co-occurring mental health conditions.

Children’s National delivers on the promise in 2024

Children's National Hospital's 2023-2024 Academic Annual Report on a tablet

The Children’s National 2023-2024 Academic Annual Report show on a tablet.

Children’s National Hospital has released its 2023-2024 Academic Annual Report, showcasing a year of transformative progress in pediatric medicine. The report highlights achievements across its research centers, institutes and Innovation Ventures, underscoring the hospital’s role as a leader in advancing child health through innovation and collaboration.

“This year’s report reflects the remarkable progress we have made in advancing the frontiers of pediatric medicine,” said Nathan Kuppermann, MD, MPH, Chief Academic Officer and Chair of Pediatrics. “It highlights groundbreaking work across our research centers, institutes, and Innovation Ventures, showcasing the collaborative spirit that drives our mission forward. These achievements underscore our shared commitment to delivering transformative research and the best possible outcomes for children and families.”

Delivering across centers

The report captures the contributions of each of Children’s National’s research centers, each pushing the boundaries of pediatric healthcare:

  • Center for Cancer & Immunology Research (CCIR): Delivering on the promise of cell and gene therapies, offering innovative treatments for pediatric cancers and immune disorders.
  • Center for Genetic Medicine Research (CGMR): Advancing pediatric genetic medicine through interdisciplinary efforts, addressing complex genetic conditions with cutting-edge science.
  • Center for Neuroscience Research (CNR): A year of growth in scientific excellence, advancing the understanding of brain development and neurological conditions.
  • Center for Prenatal, Neonatal & Maternal Health Research (CPHNMR): Revolutionizing neonatal care with its pioneering infant brain health neuromonitoring program.
  • Center for Translational Research (CTR): Facilitating groundbreaking work by new K awardees and driving translational research to bridge the gap between discovery and clinical care.
  • Sheikh Zayed Institute for Pediatric Surgical Innovation (SZI): Leading the way in advanced research projects in pediatric surgery, pushing technological boundaries to improve outcomes for children worldwide.

Taking the lead in innovation through collaboration

Innovation Ventures at Children’s National is advancing pediatric health security, addressing unique challenges with transformative solutions. Meanwhile, the Children’s National Research & Innovation Campus (CNRIC) continues to thrive as a hub for discovery and collaboration, hosting conferences on topics like artificial intelligence in healthcare, cell and gene therapy, and pediatric epilepsy research.

A vision for the future

The report also highlights Children’s National’s focus on integrating cutting-edge technologies like artificial intelligence into its research and clinical practices, as well as addressing global health challenges such as the effects of climate change on children’s health. These efforts reflect the hospital’s commitment to improving outcomes for children everywhere through innovation, teamwork, and forward-thinking leadership.

The 2023-2024 Academic Annual Report serves as a testament to the dedication and expertise of the Children’s National community, showcasing how collaboration and innovation are shaping the future of pediatric healthcare.

Advancing epilepsy care: Highlights from the 2024 American Epilepsy Society Conference

Dr. Gaillard, Dr. Schreiber and Dr. Cohen from Children’s National Hospital at the 2024 American Epilepsy Society meeting.

Dr. Gaillard, Dr. Schreiber and Dr. Cohen from Children’s National Hospital at the 2024 American Epilepsy Society meeting.

The 2024 American Epilepsy Society (AES) conference, held over five days, brought together healthcare professionals, scientists and industry leaders from around the globe. This annual event focuses on advancing outcomes for people with epilepsy through educational sessions, cutting-edge research and the latest technological innovations.

Recognized amongst his peers as an international leader in epilepsy research, William D. Gaillard, M.D., was honored with the 2024 Clinical Science Research Award at this year’s meeting. His pioneering work has significantly enhanced our understanding of epilepsy’s impact on brain structure and has led to improvements in surgical interventions and patient outcomes. Dr. Gaillard’s ongoing contributions to enhancing the lives of children with epilepsy earned him the Society’s most prestigious research award.

Dr. Gaillard serves as chief of the Divisions of Child Neurology and of Epilepsy and Neurophysiology, Director of the Comprehensive Pediatric Epilepsy Program and Associate Director of the Center for Neuroscience Research at Children’s National Hospital.

In addition to Dr. Gaillard, experts from the Comprehensive Pediatric Epilepsy Program at Children’s National were invited to present their research, insights and innovations during the conference. As a recognized Level 4 epilepsy center by the National Association of Epilepsy Centers, the program’s collaborative team is recognized worldwide for their leadership in improving the lives of children with epilepsy through personalized care, advanced technology and groundbreaking research.

Highlights from AES 2024 include:

Sanam Zarei, M.D., Children’s National Hospital Neurology fellow, presenting a poster at AES 2024.

Dr. Zarei, Children’s National Hospital Neurology fellow, presenting a poster at AES 2024.

Poster presentations:

  • Asymmetrical Hippocampal-cortical Connectivity Along Lateral-Medial Axis in Pediatric Focal Epilepsy Patients by Hua Xie, Ph.D., Chloe A. Hooker, William D. Gaillard, M.D.
  • Comorbidities and Concerns in Hypothalamic Hamartoma: Results of an International Caregiver Survey by Nathan Cohen, M.D.
  • Automated and Interpretable Detection of Hippocampal Sclerosis in temporal lobe epilepsy: AID-HS by Nathan Cohen, M.D.
  • Characteristics and Outcomes of Pediatric Patients with Prolonged Convulsive Status Epilepticus by William D. Gaillard, M.D.
  • High Accuracy for Detecting Tonic Clonic seizures (TCSs) Using an Apple Watch Seizure Detector by Dewi Depositario-Cabacar, M.D., William Gaillard, M.D.
  • Patient and Pre-surgical Testing Characteristics Contributing to Duration of Evaluation: Identifying Best Practices and Opportunities to Streamline Pediatric Epilepsy Surgery Evaluation by Dewi Depositario-Cabacar, M.D., William Gaillard, M.D.
  • Seizure Burden in Infants with Hemimegaloencephaly pre- and post Staged Transarterial Embolization by Ersida Buraniqi, M.D., Shani Israel, Lindsay Ruffini, CPNP, CPNP-AC, CPNP-PC, Tammy Tsuchida, M.D., Ph.D., Tayyba Anwar, M.D.
  • Acute Postoperative Seizures (APOS) in Pediatric Epilepsy Surgery Occurring Less Than 7 Days versus Greater Than 7 to 30 Days: Is There a Difference in Long Term Outcome? by Sanam Zarei, M.D., Kathryn Havens, PA-C, Nathan Cohen, M.D., John Schreiber, M.D., Thuy-Anh Vu, M.D., William Gaillard, M.D., Dewi Depositario-Cabacar, M.D.

Invited speakers and topics:

  • Speaker: John Schreiber, M.D., Moving Forward: Epilepsies with Concomitant Movement Disorders
  • Speaker: Laura Tochen, M.D., Moving Forward: Epilepsies with Concomitant Movement Disorders
  • Speaker: William Gaillard, M.D., US Health Care Inequities for People with Epilepsy
  • Session Moderator: Nathan Cohen, M.D., Neuroimaging

Learn more about the Comprehensive Pediatric Epilepsy Program at Children’s National Hospital.

In the news: The role of genetic testing in pediatric epilepsy diagnosis and treatment

illustration of brain with brainwaves

Given the wide variety of potential causes and seizure types, diagnosing pediatric epilepsy can be complex.

Pediatric epilepsy affects approximately 0.5-1% of children, with an increased prevalence in those with developmental disabilities. Epilepsy’s pathophysiology involves a range of factors including genetic mutations, structural brain abnormalities and metabolic disorders. Given the wide variety of potential causes and seizure types, diagnosing pediatric epilepsy can be complex.

Previously, finding the cause of pediatric epilepsy often involved laborious, piecemeal metabolic and chemical tests, making the process complicated for both patients and families. Technological advancements over the past decade, such as next-generation sequencing, have made genetic testing a vital tool in diagnosing and managing the disease through personalized treatment, leading to better outcomes.

In recent discussions, John Schreiber, M.D., explores the impact of genetic testing on pediatric epilepsy, highlighting its benefits, challenges and evolving role in treatment. Dr. Schreiber serves as Associate Chief of Epilepsy and Electroencephalography Operations, Medical Director of Electroencephalography and Medical Director of the Epilepsy Genetics Program at Children’s National Hospital.

“Genetic testing is becoming easier and less expensive to perform in patients with unexplained epilepsies, and thankfully now is being used much earlier in a patient’s epilepsy course,” Dr. Schreiber says. “It’s important to try to make that diagnosis early so we can ensure patients have the appropriate interventions early and avoid unnecessary tests and things that they don’t need.”

You can watch the full dialogue, “The Role of Genetic Testing on the Management Pediatric Epilepsy” on NeurologyLive.

Genomics solves puzzles for patients with rare disease

Drs. Berger and WIlson

Dr. Seth Berger (right) and pediatric resident Dr. Kirkland Wilson.

Most patients with rare diseases still lack answers. Families may undergo years of searching in an often painful diagnostic odyssey.

Research by Seth Berger, M.D., Ph.D., a medical geneticist in our Center for Genetic Medicine Research and Rare Disease Institute, aims to harness technologies to shorten this journey and connect families with help sooner. Dr. Berger often publishes accounts of medical mysteries he has solved.

“It’s truly stunning what genetic sequencing can find. The outcomes can be life-changing. These cases with life-altering diagnoses don’t come along every day, but when they do, they make the hunt to find answers all the more worthwhile,” says Dr. Berger.

James finds a path to health

James, age 15, struggled a lot before a researcher at Children’s National found the needle in the haystack of his genome. Four years ago, he could not walk in a straight line down the sidewalk. Enjoying Halloween trick or treating in fall or a beach hike in summer? Out of the question. His gait had become increasingly unsteady.

Everything changed the day that Dr. Berger took a look at James’ exome — a subset of the genome that can reveal mutations — to help his family find answers. Dr. Berger used advanced biochemical testing, genomic sequencing and AI to sift through the patient’s data. He found the problem: dopa-responsive dystonia, a genetic condition seen in only one out of every 1 million children. In fact, James’ case was even rarer because he had an unusual recessive form.

James and family mountain biking

James (left) rides mountain bikes with his brother, Nicholas, and mom, Shannon.

This discovery led to a cascade of positive events that transformed James’ life for the better. Thankfully, his condition has a known treatment. Laura Tochen, M.D., who directs the hospital’s Movement Disorders Program, started James on carbidopa-levodopa, a drug combination used to treat Parkinson’s disease and other neurological disorders. Within two hours, he showed improvement and his gait was almost normal.

Today, James leads an active life. On vacation last summer, he went rock climbing on real rocks for the first time. He loves mountain biking and running along the Maine coast. “He is very proud of what he can do now,” says his father, Jeff. “We are so thankful for the team that helped get him here.”

Read more stories like this one in the latest issue of Believe magazine.

Children’s National in the News: 2024

collage of news logosIn 2024, Children’s National Hospital continued to make remarkable strides across diverse areas of pediatric medicine, from groundbreaking technological innovations to critical health advocacy. The following compilation showcases ten significant stories that demonstrate the breadth and depth of the hospital’s impact, as featured in major national news outlets including NBC Nightly News, CNN, The Washington Post, The New York Times, NPR, The Today Show, Healio, and POLITICO. Delve into our 2024 news highlights for more.

1. World’s smallest pacemaker gives new hope to babies with heart defects

Charles Berul, M.D., and a patient family talk about the pill-sized pacemaker that saved the life of Abby, an infant born with deadly heart defects. (NBC Nightly News)

2. ‘A $10 death trip’: Fentanyl is killing teens. Meet one fighting for his life

Sivabalaji Kaliamurthy, M.D., addiction psychiatrist and director of the Addictions Program, spoke to CNN about the impact of drug addiction on teen health and the lack of resources available to treat opioid use disorder. (CNN)

3. Health panel urges interventions for children and teens with high BMI

Susma Vaidya, M.D., M.P.H., associate medical director of the IDEAL Clinic, shared her concerns about childhood obesity treatment recommendations issued today by a leading panel of independent U.S. health experts. (The Washington Post)

4. An Rx for food? Doctor’s offices offer groceries to those in need

Shideh Majidi, M.D., M.S.C.S., and Emily Frymark, clinical dietitian, spoke about how the food pharmacy, created in partnership with the Capital Area Food Bank, benefits patients with diabetes and other chronic conditions. (The Washington Post)

5. First patient begins newly approved sickle cell gene therapy

Kendric Cromer, a 12-year-old boy being treated at Children’s National Hospital, became the first person in the world with sickle cell disease to begin a commercially approved gene therapy that may cure the condition. “This is a big effort,” says David Jacobsohn, M.D., ScM, M.B.A. (The New York Times)

6. ‘We created this problem’: A pediatric surgeon on how gun violence affects children

Mikael Petrosyan, M.D., associate chief of General and Thoracic Surgery, discusses the stress medical staff face when treating young victims of gun violence. (NPR)

7. 7th grade boy rings bell after final round of chemotherapy

Landon, an 11-year-old patient, rang the bell at Children’s National Hospital with family, friends, doctors and nurses cheering after finishing his final round of chemotherapy. (The Today Show)

8. Study: One in three adolescents experience ‘period poverty’

Monika Goyal, M.D., M.S.C.E., pediatric emergency medicine specialist and co-director of the Center for Translational Research, emphasized the need for awareness in addressing period poverty in teenagers and young adults. (Healio)

9. The AI assurance labs are coming

Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P., vice president and chief innovation officer, participates in a panel discussion covering AI data collection, associated risks, reliance and other topics related to artificial intelligence. (POLITICO)

10. First day of a ‘new life’ for a boy with sickle cell

Children’s National patient Kendric Cromer, 12, became one of the first children ever to be treated with a newly approved gene therapy that will free him from the sickle cell disease that has stolen his childhood. (The New York Times)

The best of 2024 from Innovation District

2024 with a lightbulb instead of a zero2024 marked another groundbreaking year for Children’s National Hospital, showcasing remarkable advances across the spectrum of pediatric medicine, research and healthcare innovation. From pioneering surgical procedures to breakthrough artificial intelligence applications, the institution continued to push the boundaries of what’s possible in children’s healthcare. Read on for our list of the most popular articles we published on Innovation District in 2024.

1. Prenatal COVID exposure associated with changes in newborn brain

A study led by researchers at Children’s National Hospital showed that babies born during the COVID-19 pandemic have differences in the size of certain structures in the brain, compared to infants born before the pandemic. The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development.
(3 min. read)

2. Children’s National Hospital again ranked among the best in the nation by U.S. News & World Report

Children’s National Hospital was ranked as a top hospital in the nation by the U.S. News & World Report 2024-25 Best Children’s Hospitals annual rankings. This marks the eighth straight year Children’s National has made the Honor Roll list. The Honor Roll is a distinction awarded to only 10 children’s hospitals nationwide.
(2 min. read)

3. Children’s National performs first ever HIFU procedure on patient with cerebral palsy

In January 2023, a team of multidisciplinary doctors performed the first case in the world of using bilateral high intensity focused ultrasound (HIFU) pallidotomy on Jesus, a 22-year-old patient with dyskinetic cerebral palsy. The procedure is part of a clinical trial led by Chima Oluigbo, M.D., pediatric neurosurgeon at Children’s National Hospital.
(3 min. read)

4. Novel ultrasound device gets FDA breakthrough designation with Children’s National support

A novel ultrasound device developed by Bloom Standard received the Food and Drug Administration’s valued breakthrough device designation with the help of Children’s National Hospital. The device that enables autonomous, hands-free ultrasound scans to be performed anywhere, by any user.
(2 min. read)

5. First-of-its-kind pilot study on the impacts of Lyme disease in pregnancy and infant development

Understanding the effects of Lyme disease on the developing fetal brain is essential to ensure timely prenatal and postnatal treatments to protect the fetus and newborn. In response to this need, Children’s National Hospital is leading a pilot study to establish the groundwork needed for a larger study to determine the effect of in utero exposure to Lyme disease on pregnancy and early childhood neurodevelopmental outcomes.
(3 min. read)

6. Earliest hybrid HLHS heart surgery kids thrive 5 years later

Five years ago, Cayden was born 6 weeks early weighing less than four pounds and at risk of dying from her critical congenital heart disease. Today, she’s a happy five-year-old. Early diagnosis of her hypoplastic right ventricle, double inlet left ventricle and critical coarctation of the aorta allowed for the team at Children’s National Hospital to create a careful plan for safe delivery and to offer an innovative hybrid HLHS surgical approach at the hospital within 24 hours after she was born.
(1 min. read)

7. Wayne J. Franklin, M.D., F.A.C.C., named senior vice president of the Children’s National Heart Center

Children’s National Hospital appointed Wayne J. Franklin, M.D., F.A.C.C., as the new senior vice president (SVP) of the Children’s National Heart Center. In this role, Dr. Franklin oversees the full spectrum of heart care services including cardiac imaging and diagnostics, interventional cardiology, electrophysiology, cardiac anesthesia, cardiac surgery and cardiac intensive care.
(2 min. read)

8. Artificial – and accelerated – intelligence: endless applications to expand health equity

By pioneering artificial intelligence (AI) innovation programs at Children’s National Hospital, Marius George Linguraru, D.Phil., M.A., M.Sc., and the AI experts he leads are ensuring patients and families benefit from a coming wave of technological advances. The team is teaching AI to interpret complex data that could otherwise overwhelm clinicians.
(4 min. read)

9. Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Painting a sobering picture, a research team led by Children’s National Hospital culled years of data demonstrating that maternal mental illness is an under-recognized contributor to the death of new mothers. They called for urgent action to address this public health crisis.
(3 min. read)

10. Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics

Children’s National Hospital appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president, chief academic officer and chair of Pediatrics. In this role, Dr. Kuppermann oversees research, education and innovation for the Children’s National Research Institute as well as academic and administrative leadership in the Department of Pediatrics at George Washington University School of Medicine & Health Services.
(2 min. read)

11. First global clinical trial achieves promising results for hypochondroplasia

Researchers from Children’s National Hospital presented findings from the first clinical trial of the medication vosoritide for children with hypochondroplasia – a rare genetic growth disorder. During the phase 2 trial, researchers found vosoritide increased the growth rate in children with hypochondroplasia, allowing them to grow on average an extra 1.8 cm per year.
(2 min. read)

12. Pioneering research center aims to revolutionize prenatal and neonatal health

Since its establishment in July 2023, the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National Hospital has gained recognition through high-impact scientific publications, featuring noteworthy studies exploring the early phases of human development.
(3 min. read)

Insights and Innovations in Pediatric Neuroscience: Highlights from PNC 2024

Attendees at Sidra Medicine's 4th annual Pediatric Neuroscience Conference (PNC 2024)
Children’s National Hospital served as a strategic partner for Sidra Medicine’s 4th annual Pediatric Neuroscience Conference (PNC 2024) which took place in Doha, Qatar. This collaboration emphasizes a mutual commitment to advancing pediatric neurological care and research.

The conference offered a robust platform for presenting groundbreaking research and clinical advancements across diverse subfields such as pediatric neurology, neurosurgery, neuro-critical care, neurogenetics, neuroimmunology and neuroradiology. Esteemed medical professionals and researchers from around the world convened to share insights and innovations that are shaping the future of pediatric neurological health.

Various speakers from Children’s National led in-depth discussions on diagnostic and therapeutic innovations aimed at enhancing outcomes for children with chronic neurological and neurosurgical conditions. PNC 2024 provided an excellent platform for healthcare professionals, researchers and academics to update their knowledge and engage with leading specialists in the field.

Presenters and topics from Children’s National included:
Attendees at Sidra Medicine's 4th annual Pediatric Neuroscience Conference (PNC 2024)

The collaborative efforts with Sidra Medicine highlight a shared vision of pushing the boundaries of pediatric neurological research and treatment, ultimately aiming to improve outcomes for young patients worldwide.

Sharing development of the NeuroCardiac Critical Care Program through Congenital Heart Academy

Seven key takeaways from the early development and implementation of the NeuroCardiac Critical Care Program.

Jones presented seven key takeaways from the early development and implementation of the NeuroCardiac Critical Care Program.

“Neurodevelopmental care is not a decision on a day-to-day basis. It is a series of micro-decisions embedded in our practice every single day,” says Melissa Jones, MSN, APRN, CPNP-AC, director of the NeuroCardiac Critical Care Program at Children’s National Hospital.

Several years ago, Jones and colleagues in the Cardiac Intensive Care Unit (CICU) at Children’s National launched the program, which involved team education, implementation of evidence-based best practices, research and quality improvement efforts with the goal of optimizing brain neurodevelopment for patients in cardiac intensive care.

More than 1,000 people around the world registered for a recent virtual educational webinar hosted by the Congenital Heart Academy focused on the topics of neuroprotection for children with congenital heart disease. During the webinar the team outlined the process and lessons learned from developing this important, novel program.

What it is

The NeuroCardiac Critical Care Program at Children’s National is an integrated, multidisciplinary group of clinicians focused on eliminating secondary brain injury, optimizing brain development and promoting healthy family bonding in the CICU.

The team prioritizes several key areas, including:

  • Weekly neurodevelopmental rounds
  • Environmental changes
  • Pain and sedation management
  • Parent and caregiver engagement
  • Neuromonitoring guidelines

Jones presented the multidisciplinary team-oriented approach that led to the launch of the program, which continues to evolve and grow in the CICU today. She also offered a series of lessons learned, such as:

  • Even the patients who are the most fragile can receive developmentally supportive care.
  • Elevating and disseminating the expertise of the team is key.
  • Continuous staff educations and buy-in is essential.
  • Working with existing resources (people and material) is important.
  • Early and small wins can build traction for the team.
  • Taking care of parents is developmental care.
  • Culture change takes time, patience and persistence.

Children’s National leads the way

Children’s National is a national leader in the study of neurodevelopment across the lifespan of children born with congenital heart disease. This includes cutting edge work to understand the fetal brain, earlier diagnosis and intervention for heart disease and how congenital heart anomalies affect growth and development in utero, studies of neuroprotection strategies for use in the operating room, neurologically supportive approaches in cardiac critical care, and neuropsychological support systems as these children grow up and into adulthood.

Cardiac critical care and telehealth experts at Children’s National have been longstanding contributors to the knowledge sharing efforts of the Congenital Heart Academy from its beginning, including leading a precursor international, multi-disciplinary knowledge sharing telehealth series for critical care strategies started during the COVID-19 pandemic.

Watch the webinar: Development of the NeuroCardiac Critical Care Program

Neighborhood disadvantage alters brain networks in unborn babies

Illustration of high and low brain efficiencyGrowing up in a disadvantaged neighborhood changes a child’s brain even before birth. These new findings, in the latest edition of The Journal of Pediatrics, underscore the need to support young families from a baby’s earliest days.

According to this new research from the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National Hospital, exposure to neighborhood disadvantage lessens the functional integration of neural networks in the fetal brain, as seen on functional MRIs of healthy babies. The center compared the brains of 68 healthy babies on 79 scans. Researchers then mapped details about neural activity to a “social vulnerability index” from the Centers for Disease Control and Prevention, which indicates proximity to environmental stressors.

“We specifically looked at brain architecture to see how easily information flows between different regions,” said Kevin Cook, Ph.D., research faculty at the center and the manuscript’s first author. “To do this, we used graph theory, which borrows concepts from social network theory. It’s widely applied in computer science to understand how information flows within groups, and neuroscience has adapted it to study how information travels within the brain.”

What we found

Dr. Cook said researchers focused on the three metrics:

  • Path length, which measures how many stops information needs to make along its way through the brain.
  • Global efficiency, which measures the overall efficiency of the entire brain’s network.
  • Small-world propensity, which describes how the brain’s network is organized and indicates how well the brain is organized into smaller, efficient networks.

As social vulnerability increased, the research team found global efficiency decreased, meaning the brain’s neural network was less efficient. The path lengths were also longer in children with greater neighborhood disadvantage, reinforcing the global efficiency findings.

The fine print

The under-development and over-development of fetal brains may contribute to neurological disorders, such as autism, epilepsy and other conditions of interest to researchers. Yet science’s understanding of how the brain matures in utero is still limited.

In this study, researchers found a notable difference related to age. At the youngest gestational ages, path lengths are longer, and both global efficiency and small world propensity are lower. As the fetus gets closer to term, path length and global efficiency show rapid maturation and less advantaged fetuses catch up to their peers who have greater advantages.

Researchers saw the same findings for small-world propensity, but the maturation didn’t stop. These unborn babies overshot their peers and had greater small-world propensity, suggesting their brains are divided into a greater number of smaller networks than their advantaged peers.

“We believe that length and global efficiency are on a trend to overshoot,” Dr. Cook said. “These findings are notable because they agree with what we know about older children and adolescents. Greater disadvantage is associated with hyper- or over-maturation of the brain. Our findings suggest that this may be starting even before birth.”

What’s ahead

While still early, this research improves the understanding of how environmental complexities can impact an unborn baby. Catherine Limperopoulos, Ph.D., director of the research center, which opened in 2023, said this work will be foundational as they continue to study the impact of a child’s environment on development.

“These findings have important implications for understanding how status and disadvantage may have a cumulative effect on fetal brain development,” Dr. Limperopoulos said. “We must study and consider how to conceptualize the impact of socioenvironmental disadvantage in communities to better care for children and work to improve outcomes.”

Read the full study – “Greater Neighborhood Disadvantage Is Associated with Alterations in Fetal Functional Brain Network Structure” – in The Journal of Pediatrics.

How targeted therapy can help overcome febrile infection-related epilepsy syndrome

conceptual illustration of brain and brainwaves

In their findings, experts achieved a promising functional and neurologic outcome.

Febrile infection-related epilepsy syndrome (FIRES) is a severe neurological condition characterized by the sudden onset of seizures following a febrile illness, often leading to significant morbidity. In a recent study led by Dana Harrar, M.D., Ph.D., director of Critical Care Neurology at Children’s National Hospital, a team of experts followed the case of a 5-year-old previously healthy male who presented with acute neurological decline. This culminated in super-refractory status epilepticus following a fever.

The study outlines a novel treatment regimen that involved early and aggressive cytokine-directed immunomodulatory therapy, alongside a comprehensive seizure management strategy that intentionally avoided barbiturate use. By tailoring treatment to the patient’s evolving cytokine profile and incorporating supportive measures such as the ketogenic diet and antiseizure medications, experts achieved a promising functional and neurologic outcome.

“Now, 2½ years later, he attends mainstream school, has attention-deficit hyperactivity disorder (ADHD), mild neurocognitive impairment and well-controlled epilepsy,” the experts write. “By using cytokine-directed immunotherapy and avoiding a barbiturate coma, we were able to successfully treat a pediatric patient with febrile infection-related epilepsy syndrome and achieve a good outcome.”

The study’s findings show that the understanding of FIRES is advancing as experts uncover the underlying mechanisms of this challenging neurological disorder. Physician-scientists in this field developed innovative treatment strategies targeting immune dysregulation and associated seizures. By following recent consensus recommendations and utilizing molecularly targeted immunotherapy along with serial cytokine profiling, Dr. Harrar and team successfully treated the 5-year-old patient, leading to a positive neurological outcome.

You can read the full study, Successful Management of Febrile Infection-Related Epilepsy Syndrome Using Cytokine-Directed Therapy, in the Journal of Child Neurology.

Children’s National again ranked among the best in the nation by U.S. News & World Report

2024-25 US News BadgesChildren’s National Hospital in Washington, D.C., was ranked as a top hospital in the nation by the U.S. News & World Report 2024-25 Best Children’s Hospitals annual rankings. This marks the eighth straight year Children’s National has made the Honor Roll list. The Honor Roll is a distinction awarded to only 10 children’s hospitals nationwide.

This year, U.S. News ended ordinal rankings on its Honor Roll. Instead of assigning a numerical rank from 1 to 10, all hospitals on the Honor Roll will be recognized as having attained the highest standards of care in the nation.

In addition, Children’s National tied for #1 pediatric hospital in the Mid-Atlantic region, which includes New York, New Jersey, Delaware, Pennsylvania, the District of Columbia, West Virginia and Virginia. It’s also best in the Mid-Atlantic in Neonatology.

For the fourteenth straight year, Children’s National ranked in 10 specialty services. New this year, U.S. News included behavioral health as a service line in the rankings. Since it’s the first year, there are no ordinal rankings for behavioral health, but the Children’s National program was named one of the top 50 programs in the country.

“In my first year here, I witnessed what makes Children’s National so special — our commitment to collaboration, empowering one another, and charting a bold path forward for pediatric care,” said Michelle Riley-Brown, MHA, FACHE, president and chief executive officer of Children’s National. “I’m proud U.S. News again recognized Children’s National as one of the top in the nation and the highest-ranked pediatric hospital in D.C., Maryland and Virginia. Together, we’ll continue to push the boundaries of care, research and innovation to make a difference for those who matter most — the kids.”

The annual rankings are the most comprehensive source of quality-related information on U.S. pediatric hospitals and recognizes the nation’s top 50 pediatric hospitals based on a scoring system developed by U.S. News.

“For nearly two decades, U.S. News has published Best Children’s Hospitals to empower the parents and caregivers of children with complex medical needs,” said Ben Harder, chief of health analysis and managing editor at U.S. News. “Children’s hospitals appearing on the U.S. News Honor Roll have a track record of delivering unparalleled specialized care.”

The bulk of the score for each specialty service is based on quality and outcomes data. The process includes a survey of relevant specialists across the country, who are asked to list hospitals they believe provide the best care for patients with the most complex conditions.

The Children’s National specialty services that U.S. News ranked in the top 10 nationally are:

The other four specialties ranked among the top 50 are Behavioral Health, Cardiology and Heart Surgery, Pulmonology and Lung Surgery, and Urology.